MindWalk Holdings

Name

MindWalk Holdings

Legal name

MindWalk Holdings Corp.

Website

https://mindwalkai.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

AI-Powered Biologics Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Bio-Native AI drug discovery
• Antibody discovery platforms
• Biological data analytics
• AI-powered biologics research
• Immunogenicity screening

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others

Revenue model

1. LensAI SaaS Platform Contracts: MindWalk generates contracted recurring platform revenue from its LensAI SaaS platform under enterprise one-year agreements with life-sciences customers. This represents a strategic shift from project-based revenue to recurring revenue.
2. Custom Discovery Services and Lab Research: Project-based fee-for-service revenue from antibody discovery, advanced lab research, therapeutic discovery, anti-drug antibody discovery, diagnostic antibody discovery, and protein engineering and production services delivered to pharmaceutical and biotech company partners.
3. Licensing and IP: MindWalk's patent filings (European patent application EP26187897.9) and HYFT foundational patent (WO 2020/161344) support potential future licensing revenue from its biological data layer technology. The company is building toward licensing its data layer architecture to pharmaceutical partners.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

MindWalk Holdings operates a BioIntelligence Ecosystem that combines Bio-Native AI software with advanced wet-lab research for therapeutic antibody, peptide, and vaccine discovery. Its LensAI SaaS platform, built on the proprietary HYFT biological pattern technology and the ReefIQ biological context layer, enables target discovery, candidate diligence, epitope mapping, immunogenicity screening, developability assessment, and agentic AI workflows for pharmaceutical and biotech customers. The company also delivers custom biologics discovery services through laboratories in Canada, the United States, and Belgium.

Product overview

MindWalk Holdings offers a BioIntelligence Ecosystem combining Bio-Native AI, deep biological data, and advanced lab research for biologics discovery. The platform architecture consists of three integrated layers: HYFT® Technology as the core biological pattern and representation foundation (660 million biological patterns, 25 billion relationships), ReefIQ™ as the biological context layer that harmonizes and governs client discovery data, and LensAI™ as the reasoning and application layer enabling target discovery, epitope mapping, immunogenicity screening, and agentic AI workflows. Supporting wet lab services include B cell Select® and B cell Llama™ discovery platforms for antibody and nanobody identification. The ecosystem also includes a Pandemic Response Platform for RNA virus outbreak preparedness.

Differentiator

Problem solved

Functional benefit

Brands

• HYFT: Core biological pattern technology and AI-ready data substrate powering MindWalk's drug discovery platforms, representing 660 million biological patterns and 25 billion relationships.
• LensAI
• ReefIQ
• B cell Select
• B cell Llama
• Pandemic Response Platform
• BioStrand

Products and services

• LensAI SaaS Platform Cloud-based AI-powered reasoning and application layer that operates on the HYFT biological pattern substrate and ReefIQ context layer. Enables target discovery, candidate diligence, epitope mapping, immunogenicity screening, developability assessment, hypothesis generation, and portfolio decision support for pharmaceutical and biotechnology R&D teams, with capabilities for agentic AI workflow deployment.
• ReefIQ Biological Context Layer Biological context layer that connects fragmented biological data—sequences, structures, assay outputs, omics data, literature, evidence, provenance, and program history—into governed, queryable, connected context. Sits between client discovery data and AI reasoning tools such as LensAI and exposes governed context to customer-selected agent models operating within agreed governance.
• B cell Llama Nanobody Discovery Platform B cell Llama discovery platform for nanobody candidate identification targeting the bispecific antibody market. Combines B cell discovery workflows with LensAI in silico screening for developability and immunogenicity assessment to support bispecific antibody development programs.
• B cell Select Antibody Discovery Platform B cell discovery platform that generates diverse panels of antibodies with desirable binding characteristics through immunization and antigen-specific B cell enrichment workflows. Integrated with LensAI for downstream in silico screening, developability, and immunogenicity analysis.
• Pandemic Response Platform Deployment configuration of the HYFT biological pattern system and LensAI platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. Targets government, biodefense, and public-health customers needing rapid response within frameworks such as the CEPI 100 Days Mission.
• Advanced Lab Research Services Integrated wet-lab research services for antibody discovery and development delivered by MindWalk's scientific teams. Supports therapeutic antibody, anti-drug antibody, diagnostic antibody, peptide, and vaccine programs and combines wet-lab workflows with Bio-Native AI and deep biological data.
• Biologics Discovery Services Comprehensive custom biologics discovery services for pharmaceutical and biotech partners covering therapeutic antibody discovery, anti-drug antibody discovery, diagnostic antibody discovery, therapeutics discovery, and protein engineering and production. Delivered by dedicated scientific teams at MindWalk's lab sites in Canada, the United States, and Belgium.

Quantifiable outcome

• LensAI epitope mapping achieves AUC values of approximately 0.8 and above, closely matching X-ray crystallography precision, in hours instead of months.
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Absci (NASDAQ: ABSI)coreStrategic or Co-development Partner · 15 June 2026MindWalk's CEO Dr. Jennifer Bath joined a virtual panel at Jones AI Day on June 15, 2026, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider to discuss the convergence of high-performance computing, biological knowledge representations, and generative AI in drug discovery. The panel explored Bio-Native AI and agentic AI applications in drug development, including addressing longstanding barriers such as prolonged screening timelines and undruggable targets.
• AMD (Advanced Micro Devices)coreTechnology or Integration · 9 December 2025MindWalk deployed AMD Instinct MI300X GPUs and EPYC CPUs on Vultr cloud to power its LensAI drug discovery platform. The implementation delivered approximately 39% lower cost per million samples in literature mining and about 70% higher embedding throughput compared to prior infrastructure. AMD EPYC processors screened over 170,000 antibody pairs in approximately 4.5 hours versus an estimated 145 days on previous infrastructure.
• Vultr CloudcoreTechnology or Integration · 9 December 2025MindWalk deployed its LensAI platform on Vultr cloud infrastructure alongside AMD hardware, enabling pharmaceutical scientists to run larger protein language models and biological analysis faster.
• ArgenxminorStrategic or Co-development PartnerArgenx is referenced in connection with MindWalk's published research in Nature (scientific publication collaboration).
• GenmabminorStrategic or Co-development PartnerMindWalk and Genmab entered into a technology partnership targeting infectious disease, as referenced in a PR Newswire announcement.
• Janssen Pharma (Johnson & Johnson)minorStrategic or Co-development PartnerMindWalk announced an agreement with Janssen (a Johnson & Johnson company) as referenced in a PR Newswire announcement covering antibody discovery collaboration.
• NIH (National Institutes of Health)minorStrategic or Co-development PartnerMindWalk collaborated with the NIH and Integrated Biotherapeutics to study structural details of antibodies with therapeutic potential to treat or prevent COVID-19, as referenced in a PR Newswire announcement.
• Novo NordiskminorStrategic or Co-development PartnerNovo Nordisk is referenced in connection with MindWalk's published research, as cited in the EMBO Press publication.
• MJ Fox FoundationminorStrategic or Co-development PartnerMindWalk collaborated with the MJ Fox Foundation on research referenced in a PubMed publication (PMID: 38293125).

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AbCellera Biologics: Public antibody discovery platform using single-cell screening and AI/ML for therapeutic antibody identification. Closely comparable to MindWalk's B cell Select/Llama discovery platforms, with stronger financial scale.
• Exscientia: AI-driven precision medicine company using AI-based discovery for small-molecule drug design with pharma partnerships. Comparable in operating model (AI platform + pharma collaborations) though stronger in small molecules than antibodies.
• Recursion Pharmaceuticals: AI-native drug discovery platform combining high-throughput wet-lab experimentation with proprietary foundation models. Directly comparable to MindWalk as a publicly-traded AI-driven biology platform targeting small-molecule and biologic discovery for pharma partners.
• Insitro: Machine learning-driven drug discovery platform combining high-throughput biology with predictive models for target identification and patient stratification. Comparable to MindWalk in the AI drug discovery category with strong pharma partnerships.
• Absci: Generative AI drug creation company focused on de novo antibody design using proprietary foundation models. Shares the AI-for-biologics positioning and was featured alongside MindWalk's CEO at the Jones AI Day panel.

Emerging players

• BigHat Biosciences: AI/ML platform for antibody design combining machine learning with high-throughput wet-lab characterization. Direct overlap on antibody discovery and developability assessment; emerging private player in the same AI antibody niche.
• Generate Biomedicines: Generative biology platform designing novel protein therapeutics using AI foundation models. Comparable in pursuing generative AI for protein/antibody design with significant venture backing.
• Adimab: Private antibody discovery company using a yeast-based platform to generate and optimize therapeutic antibodies. Comparable to MindWalk's wet-lab antibody discovery services with strong pharma partnership track record.

Broad incumbents

• Schrödinger: Computational chemistry and biology platform offering physics-based software (LiveDesign) plus drug discovery services. Broader incumbent in computational life sciences with overlapping AI-driven biologics capability.
• Charles River Laboratories: Large CRO providing drug discovery, development, and manufacturing services including antibody and biologics capabilities. Comparable to MindWalk's lab-services business as an incumbent CRO with biologics expertise, though at vastly greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mindwalkcorp
• YouTubeyoutube.com/@mindwalkAI
• LinkedInlinkedin.com/company/mindwalkcorp

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MindWalk Holdings